Pipeline

Disease area

Product

Compound

Indication

Phase I

Phase II

Phase III

Agitation in dementia of the Alzheimer’s type

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Find the specific study here: www.clinicaltrials.gov/NCT01922258 and www.clinicaltrials.gov/NCT03594123

 

 

      

Post-Traumatic Stress Disorder

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of Post-Traumatic Stress Disorder.

For more information and study locations, please visit www.clinicaltrials.gov

 

      

     

Borderline Personality Disorder Rexulti Brexpiprazole Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of Borderline Personality Disorder.            

Parkinson's Disease

 

Foliglurax

Foliglurax is a small-molecule positive allosteric modulator of group III metabotropic glutamate receptor 4 (mGluR4 PAM) for the potential oral treatment of Parkinson's disease.

Read the specific study here: www.clinicaltrials.gov/NCT03162874

 

      

 

Schizophrenia  

Lu AF11167

Lu AF11167 is a potent and selective inhibitor of the PDE10A enzyme and is in development as a monotherapy treatment of negative symptoms in clinically stable (positive symptom controlled) patients with schizophrenia.

Read the specific study here www.clinicaltrials.gov/NCT03793712

 

      

 
Tourette Syndrome   ABX - 1431

The lead molecule ABX - 1431 is a potent selective inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL) that potentiates endocannabinoid signalling to restore homeostatic balance in the central nervous system. 

Read the specific study here https://clinicaltrials.gov/NCT03625453

        

Schizophrenia 2 months

Abilify Maintena

Aripiprazole once-monthly

Aripiprazole once-monthly is an intramuscular injection indicated for the treatment of schizophrenia once-monthly. It is further in development as a potential 2 months’ treatment of schizophrenia.

For more information and study locations, please visit www.clinicaltrials.gov

      

 

 

Parkinson’s Disease

  Lu AF28996

Lu AF28996 is a D1/D2 agonist in development targeting moderate to advanced Parkinson’s disease patients with motor fluctuations.

Read the specific study here: www.clinicaltrials.gov/NCT03565094

      

   

Parkinson’s Disease

  Lu AF82422

Lu AF82422 is a human IgG1 mAb that recognizes all major species of alpha-synuclein. Extracellular alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease.

Read the specific study here www.clinicaltrials.gov/NCT03611569

      

 

 
Neuropathic Pain   ABX - 1431            

 

 

 

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.